Reached enrollment goal of 305 patients living with Type 1 or Type 2 diabetes Primary endpoint analysis expected in 4Q 2024 Data dissemination and FDA submission expected in 2025 INHALE-1 is a 26-week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results